Rachel Humphrey's Net Worth
$1.03 Million
Who is Rachel Humphrey?
Rachel Humphrey has an estimated net worth of $1.03 Million. This is based on reported shares across multiple companies, which include Mirati Therapeutics, Inc., Xilio Therapeutics, Inc., Pyxis Oncology, Inc., CytomX Therapeutics, Inc., and Black Diamond Therapeutics, Inc..
SEC CIK
Rachel Humphrey's CIK is 0001579781
Past Insider Trading and Trends
2018 was Rachel Humphrey's most active year for acquiring shares with 3 total transactions. Rachel Humphrey's most active month to acquire stocks was the month of December. 2018 was Rachel Humphrey's most active year for disposing of shares, totalling 4 transactions. Rachel Humphrey's most active month to dispose stocks was the month of January. 2018 saw Rachel Humphrey paying a total of $264,588.00 for 140,000 shares, this is the most they've acquired in one year. In 2018 Rachel Humphrey cashed out on 80,000 shares for a total of $1,200,000.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Mirati Therapeutics, Inc. (MRTX) No price found
EVP and Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Xilio Therapeutics, Inc. (XLO) Snapshot price: $0.64
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Pyxis Oncology, Inc. (PYXS) Snapshot price: $3.71
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +66.72% | 38.74K |
—
|
—
| 96.81K |
Mar 26
| |||
Form 4
|
∞
| 58.06K |
—
|
—
| 58.06K |
Mar 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
CytomX Therapeutics, Inc. (CTMX) Snapshot price: $1.44
Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 25
| |||
Form 4
|
—
|
0
|
$18.31 | -$377,906.45 | 30.23K |
Scheduled
|
Mar 2
| ||
Form 4
|
—
|
0
|
$18.31 | -$557,505.55 | 30.23K |
Scheduled
|
Feb 28
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 24
| |||
Form 4
| +100.00% | 15.12K |
$6.61 | $99,994.42 | 30.23K |
Dec 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 25
| |||
Form 4
|
∞
| 15.12K |
$6.61 | $99,994.42 | 15.12K |
Dec 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Black Diamond Therapeutics, Inc. (BDTX) Snapshot price: $3.86
Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 17
| |||
Form 4
|
∞
| 10K |
—
|
—
| 10K |
Sep 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |